• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Autoimmune-Related Primary Hypoparathyroidism Possibly Induced by the Administration of Pembrolizumab: A Case Report.

作者信息

Umeguchi Hitomi, Takenoshita Hiromasa, Inoue Hiroshi, Kurihara Yuki, Sakaguchi Chihiro, Yano Seiichi, Hasuzawa Nao, Sakamoto Shohei, Sakamoto Ryuichi, Ashida Kenji

机构信息

Karatsu Red Cross Hospital, Karatsu; and Kyushu University, Fukuoka, Japan.

出版信息

J Oncol Pract. 2018 Jul;14(7):449-451. doi: 10.1200/JOP.18.00076. Epub 2018 Jun 15.

DOI:10.1200/JOP.18.00076
PMID:29906213
Abstract
摘要

相似文献

1
Autoimmune-Related Primary Hypoparathyroidism Possibly Induced by the Administration of Pembrolizumab: A Case Report.帕博利珠单抗给药可能诱发的自身免疫性相关原发性甲状旁腺功能减退症：一例报告
J Oncol Pract. 2018 Jul;14(7):449-451. doi: 10.1200/JOP.18.00076. Epub 2018 Jun 15.
2
Real-World Experience With Pembrolizumab in Patients With Advanced Lung Cancer.帕博利珠单抗治疗晚期肺癌患者的真实世界经验
Am J Ther. 2019 Jul/Aug;26(4):e537-e538. doi: 10.1097/MJT.0000000000000762.
3
Focal immune-related pancreatitis occurring after treatment with programmed cell death 1 inhibitors: a distinct form of autoimmune pancreatitis?程序性细胞死亡蛋白1抑制剂治疗后发生的局灶性免疫相关性胰腺炎：自身免疫性胰腺炎的一种独特形式？
Eur J Cancer. 2018 May;95:123-126. doi: 10.1016/j.ejca.2018.02.006. Epub 2018 Mar 9.
4
Complete Atrioventricular Block Associated with Pembrolizumab-induced Acute Myocarditis: The Need for Close Cardiac Monitoring.帕博利珠单抗诱导的急性心肌炎相关的完全性房室传导阻滞：密切心脏监测的必要性
Intern Med. 2018 Nov 1;57(21):3157-3162. doi: 10.2169/internalmedicine.0255-17. Epub 2018 Jun 6.
5
Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.纳武利尤单抗治疗后进展的晚期非小细胞肺癌患者接受帕博利珠单抗治疗：12 例病例的报告。
Cancer Chemother Pharmacol. 2018 Jun;81(6):1105-1109. doi: 10.1007/s00280-018-3585-9. Epub 2018 Apr 19.
6
Immune Checkpoint Inhibitor-Induced Hypoparathyroidism Associated With Calcium-Sensing Receptor-Activating Autoantibodies.免疫检查点抑制剂相关低钙血症与钙敏感受体激活自身抗体。
J Clin Endocrinol Metab. 2019 Feb 1;104(2):550-556. doi: 10.1210/jc.2018-01151.
7
Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer.非小细胞肺癌中检查点抑制剂诱导的毒性作用与共享的癌症和组织抗原的关系。
JAMA Oncol. 2019 Jul 1;5(7):1043-1047. doi: 10.1001/jamaoncol.2019.0402.
8
There and back again: An immunotherapy tale.往返之间：一个免疫疗法的故事。
J Thorac Cardiovasc Surg. 2018 Apr;155(4):1771-1774. doi: 10.1016/j.jtcvs.2017.11.102. Epub 2017 Dec 23.
9
Tracheoesophageal Fistula Caused by Successful Response to Pembrolizumab in a Patient With Squamous Cell Lung Cancer.一名鳞状细胞肺癌患者对帕博利珠单抗治疗成功应答后引发的气管食管瘘
J Thorac Oncol. 2019 Jul;14(7):e141-e143. doi: 10.1016/j.jtho.2019.02.013.
10
Cytokine Release Syndrome with Pseudoprogression in a Patient with Advanced Non-Small Cell Lung Cancer Treated with Pembrolizumab.帕博利珠单抗治疗晚期非小细胞肺癌患者时出现细胞因子释放综合征伴假性进展
J Thorac Oncol. 2019 Mar;14(3):e55-e57. doi: 10.1016/j.jtho.2018.11.025.

引用本文的文献

1
Secondary Adrenal Insufficiency Due to Isolated ACTH Deficiency Induced by Pembrolizumab: A Report of Two Cases of Uterine Endometrial Cancer.帕博利珠单抗诱发孤立性促肾上腺皮质激素缺乏所致的继发性肾上腺皮质功能不全：两例子宫内膜癌病例报告
Reports (MDPI). 2023 Apr 17;6(2):18. doi: 10.3390/reports6020018.
2
Hypoparathyroidism induced by immune checkpoint inhibitors: a review of literature reports and real-world pharmacovigilance data.免疫检查点抑制剂诱发的甲状旁腺功能减退：文献报道与真实世界药物警戒数据综述
Endocr Connect. 2025 Jul 12;14(7). doi: 10.1530/EC-25-0123. Print 2025 Jul 1.
3
An Extremely Rare Case of Immune Checkpoint Inhibitors-Related Hypoparathyroidism and a Critical Literature Review.
免疫检查点抑制剂相关甲状旁腺功能减退症的一例极其罕见病例及文献综述
JCEM Case Rep. 2025 May 12;3(6):luaf097. doi: 10.1210/jcemcr/luaf097. eCollection 2025 Jun.
4
Management, biomarkers and prognosis in people developing endocrinopathies associated with immune checkpoint inhibitors.免疫检查点抑制剂相关内分泌病患者的管理、生物标志物与预后
Nat Rev Endocrinol. 2025 May;21(5):289-300. doi: 10.1038/s41574-024-01077-6. Epub 2025 Jan 9.
5
Life-Threatening Endocrinological Immune-Related Adverse Events of Immune Checkpoint Inhibitor Therapy.免疫检查点抑制剂治疗危及生命的内分泌免疫相关不良事件。
Cancers (Basel). 2023 Dec 10;15(24):5786. doi: 10.3390/cancers15245786.
6
Immune Checkpoint Inhibitor-Induced Endocrine Adverse Events in Cancer Patients at a Tertiary Care Center in Saudi Arabia.沙特阿拉伯一家三级医疗中心癌症患者中免疫检查点抑制剂诱发的内分泌不良事件
Cureus. 2023 Aug 28;15(8):e44296. doi: 10.7759/cureus.44296. eCollection 2023 Aug.
7
Hypoparathyroidism: an uncommon adverse effect of treatment with durvalumab.甲状旁腺功能减退：度伐利尤单抗治疗的一种罕见不良反应。
Endocr Oncol. 2022 Sep 22;2(1):K21-K24. doi: 10.1530/EO-22-0047. eCollection 2022 Jan.
8
The Uncharted Landscape of Rare Endocrine Immune-Related Adverse Events.罕见内分泌免疫相关不良事件的未知领域
Cancers (Basel). 2023 Mar 28;15(7):2016. doi: 10.3390/cancers15072016.
9
Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline.接受免疫检查点抑制治疗患者的内分泌相关不良事件：ESE 临床实践指南。
Eur J Endocrinol. 2022 Oct 25;187(6):G1-G21. doi: 10.1530/EJE-22-0689. Print 2022 Dec 1.
10
Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy.接受免疫治疗的癌症患者中与免疫相关的罕见不良事件
Diagnostics (Basel). 2022 Aug 29;12(9):2091. doi: 10.3390/diagnostics12092091.